Literature DB >> 10915021

Enhanced sensitivity to alkylating agent in lymphocytes from patients with multiple endocrine neoplasia type 1.

Y Itakura1, A Sakurai, M Katai, Y Ikeo, K Hashizume.   

Abstract

Chromosome instability is known to be associated with certain autosomal recessive cancer-prone disorders such as Fanconi's anemia. Multiple endocrine neoplasia type 1 (MEN 1) is an autosomal dominant disorder characterized by development of tumors in two or more endocrine organs, and chromosome instability in patients with MEN 1 has been described. The clinical features of MEN 1 are, however, distinct from other DNA instability syndromes except predisposition to tumors. Therefore, we reevaluated chromosome instability in patients with familial MEN 1. An increase in the frequency of chromosome aberrations was observed in MEN 1 patients but not in control subjects when peripheral mononuclear cells were exposed to an alkylating agent, diepoxybutane (DEB). DEB reduced survival of mononuclear cells in a dose-dependent manner in both MEN 1 patients and control subjects, but this effect was more prominent in MEN I patients. There was no apparent correlation between certain MEN1 gene mutations and sensitivity to DEB. From these results, we conclude that hypersensitivity to alkylating agents exists in patients with MEN 1. Molecular mechanisms of this phenomenon and relationship to tumorigenesis in endocrine organs should be elucidated.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10915021     DOI: 10.1016/s0753-3322(00)80041-4

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  9 in total

Review 1.  In search of tumor suppressing functions of menin.

Authors:  Yuqing Yang; Xianxin Hua
Journal:  Mol Cell Endocrinol       Date:  2007-01-11       Impact factor: 4.102

2.  MEN1 and FANCD2 mediate distinct mechanisms of DNA crosslink repair.

Authors:  Lorri R Marek; Molly C Kottemann; Peter M Glazer; Allen E Bale
Journal:  DNA Repair (Amst)       Date:  2008-02-06

3.  Menin induces apoptosis in murine embryonic fibroblasts.

Authors:  Robert W Schnepp; Hua Mao; Stephen M Sykes; Wei-Xing Zong; Albert Silva; Ping La; Xianxin Hua
Journal:  J Biol Chem       Date:  2003-12-18       Impact factor: 5.157

4.  Direct binding of DNA by tumor suppressor menin.

Authors:  Ping La; Albert C Silva; Zhaoyuan Hou; Haoren Wang; Robert W Schnepp; Nieng Yan; Yigong Shi; Xianxin Hua
Journal:  J Biol Chem       Date:  2004-08-24       Impact factor: 5.157

5.  MEN1 is a melanoma tumor suppressor that preserves genomic integrity by stimulating transcription of genes that promote homologous recombination-directed DNA repair.

Authors:  Minggang Fang; Fen Xia; Meera Mahalingam; Ching-Man Virbasius; Narendra Wajapeyee; Michael R Green
Journal:  Mol Cell Biol       Date:  2013-05-06       Impact factor: 4.272

6.  The 32-kilodalton subunit of replication protein A interacts with menin, the product of the MEN1 tumor suppressor gene.

Authors:  Karen E Sukhodolets; Alison B Hickman; Sunita K Agarwal; Maxim V Sukhodolets; Victor H Obungu; Elizabeth A Novotny; Judy S Crabtree; Settara C Chandrasekharappa; Francis S Collins; Allen M Spiegel; A Lee Burns; Stephen J Marx
Journal:  Mol Cell Biol       Date:  2003-01       Impact factor: 4.272

7.  Distinct pathways regulated by menin and by MLL1 in hematopoietic stem cells and developing B cells.

Authors:  Bin E Li; Tao Gan; Matthew Meyerson; Terence H Rabbitts; Patricia Ernst
Journal:  Blood       Date:  2013-08-01       Impact factor: 22.113

8.  Multiple endocrine neoplasia type 1 associated with breast cancer: A case report and review of the literature.

Authors:  Young Ju Jeong; Hoon Kyu Oh; Jin Gu Bong
Journal:  Oncol Lett       Date:  2014-05-13       Impact factor: 2.967

Review 9.  Multiple endocrine neoplasia type 1 (MEN1) as a cancer predisposition syndrome: clues into the mechanisms of MEN1-related carcinogenesis.

Authors:  Valeria Busygina; Allen E Bale
Journal:  Yale J Biol Med       Date:  2006-12
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.